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Abstract
Aims: To examine the effect of updating a systematic review of nicotine replacement therapy on
its contents and conclusions.
Methods: We examined the effects of regular updating of a systematic review of nicotine
replacement therapy for smoking cessation. We considered two outcomes. First, we assessed the
effect of adding new data to meta-analyses, comparing results in 2000 with the results in 1994.
Second, we assessed qualitatively the ways inwhich the nature of the questions addressed by the
review had changed between the two dates. For the first outcome, we compared the number of
trials, the pooled estimate of effect using the odds ratio, and the results of pre-specified subgroup
analyses, for nicotine gum and patch separately. Using a test for interaction, we assessed whether
differences between estimates were statistically significant.
Results: There were ten new trials of nicotine gum between 1994 and 2000, and the meta-analytic
effect changed little. For the nicotine patch the number of trials increased from 9 to 30, and the
meta-analytic effect fell from 2.07 (95% CI 1.64 – 2.62) to 1.73 (95% CI 1.56 – 1.93). Apparent
differences in relative effect in sub-groups found in 1994 were not found in 2000. The updated
systematic review addressed a number of questions not identified in the original version.
Conclusions: Updating the meta-analyses lead to a more precise estimate of the likely effect of
the nicotine patch, but the clinical message was unchanged. Further placebo controlled NRT trials
are not likely to add to the evidence base. It is questionable whether updating the meta-analyses to
include them is worthwhile. The content of the systematic review has, however, changed, with the
addition of data addressing questions not considered in the original review. There is a tension
between the principle of identifying the important questions prior to conducting a review, and
keeping the review up to date as primary research identifies new avenues of enquiry.
Background
There have been over 90 trials of nicotine replacement
therapy for helping people to stop smoking. The most re-
liable estimate of the effectiveness of a treatment comes
from considering all the available evidence. Meta-analy-
sis of clinical trials provides a quantitative estimate of
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tients studied. It also has the potential to explore,
through pre-specified sub-group analysis, whether effec-
tiveness varies by other clinical variables, such as setting
of care or patient population.
Previous research has shown that updating can affect
both the direction and the precision of the estimate of
treatment effects. [1] Clinically, whether a treatment is
considered effective can depend crucially on updating
meta-analysis as new evidence becomes available. [2]
However, there are questions about updating that re-
main unanswered. In particular, is there a point in the
research process where updating can add nothing fur-
ther and should be abandoned? Since 1996, The Co-
chrane Tobacco Addiction review group has annually
updated a systematic review of nicotine replacement
therapy for smoking cessation, first published in 1994.
[3,4] Updating consumes significant resources, and we
wished to determine what we had achieved by regular
updating.
Our objectives were
To describe changes in the number and type of trials in-
cluded in the review
To determine whether updating lead to statistically sig-
nificant changes in estimates of the effectiveness of NRT.
To determine whether updating lead to statistically sig-
nificant changes in estimates of effectiveness by intensity
of behavioural support, and by setting of treatment. To
determine whether the relative effects of treatment in
different versions of the review were affected by differ-
ences in setting of treatment, level of behavioural sup-
port or length of follow-up.
To determine how the content of the review had changed
measured by changes in the questions addressed.
Methods
We describe the methods of the systematic review else-
where.(4) In brief, we collect data from randomised trials
with at least six months follow-up. We calculate the ef-
fects of treatment as odds ratios with values larger than
1.0 indicating that intervention leads to more people
stopping smoking. We calculate the odds ratios using the
Peto method after testing for heterogeneity. [5]
In addition to assessing the effects of NRT compared to
placebo, we pre-specify two subgroup analyses. Because
the effect of treatment interacts with patient characteris-
tics, particularly motivation, we wished to know whether
treatment effects differ by the setting in which they were
recruited. Thus we compared the odds ratios in studies
recruiting through advertising in the community, in pri-
mary care, in smoking cessation clinics or in hospitals.
The second sub-group analysis categorises the trials as
high or low intensity, depending on the amount of behav-
ioural support given as an adjunct to the pharmacologi-
cal therapy. In addition, in this review we explored a
further sub-group analysis to address the methodologi-
cal issue of whether the pooled estimates differed for tri-
als with different durations of follow-up. In this study we
compared the results of the meta-analysis in 1994 and
2000. We assessed the difference between estimates in
subgroups of trials using a Z-test for interaction. For
each sub-group, we calculated the standard error of the
log odds from the pooled odds ratio and 95% confidence
interval. We then calculated the standard error of the dif-
ference of the two log odds from the square root of the
sum of the squared standard errors. The test statistic was
then the difference in the log odds divided by its standard
error.
Results
Figure 1 shows the number of studies comparing each
type of NRT with a placebo/no NRT control, and studies
addressing dose, type or combination therapy, by two
year period. Most research reported since 1994 has been
on the nicotine patch. Tables 1 & 2 compares the meta-
analytic estimates in 1994 with those in 2000 for nico-
tine gum and nicotine patch.
Nicotine gum
In 1994 the odds ratio for nicotine gum compared to pla-
cebo, based on 38 trials was 1.64 (95% CI 1.48 – 1.81). By
2000 there were ten further trials. The pooled estimate
was little changed: OR 1.63 (95% CI 1.49 – 1.79).) (Table
1a)
Figure 1
Number of nicotine replacement therapy trials included in
review, 1994–2000
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ceived both high intensity support and nicotine gum. In
1994 the estimate of the relative efficacy of gum com-
pared to control was higher with minimal support than
with intensive support, although the difference was not
statistically significant. The results in 2000 show little
difference. (Table 1b).
Nicotine patch
In 1994 the odds ratio for nicotine patch was 2.07 (95%
CI 1.64 – 2.62). In 2000 the odds ratio was 1.73 (95% CI
1.56 – 1.93). (Table 2a) In 1994 the meta-analysis includ-
ed data from 2,213 participants in 9 trials. In 2000 the
meta-analysis included almost 16,000 patients in 30 tri-
als. In 2000 the largest 6 trials, whether by size or weight
in the meta-analysis, contained almost 60% of the partic-
ipants. Only one of the trials available in 1994 is amongst
Table 1: Comparison between review results for nicotine gum in 1994 and 2000
Review year 1994 2000
a) All trials No. of trials 38 48
Odds ratio 1.64 1.63
95% CI 1.48–1.81 1.49–1.79
Χ2 & p for heterogeneity 43.94 (p = 0.2) 55.22 (p = 0.19)
b) Level of support sub group*: No. of trials 17 19
-Low intensity Odds ratio 1.81 1.72
95% CI 1.54–2.12 1.48–2.00
Χ2 & p for heterogeneity 22.76 (p = 0.12) 25.71 (p = 0.11)
-High intensity No. of trials 18 25
Odds ratio 1.55 1.56
95% CI 1.33–1.80 1.37–1.78
Χ2 & p for heterogeneity 17.44 (p = 0.42) 22.61 (p = 0.54)
*Level of support could not be assessed for all trials.
Table 2: Comparison between review results for nicotine patch in 1994 and 2000
Review year 1994 2000
a) All trials No. of trials 9 30
Odds ratio 2.07 1.73
95% CI 1.64–2.62 1.56–1.93
Χ2 & p for heterogeneity 7.08 (p = 0.53) 41.75(p = 075)
b) Level of support sub group: No. of trials 4 12
-Low intensity Odds ratio 2.52 1.74
95% CI 1.64–3.87 1.48–2.04
Χ2 & p for heterogeneity 4.84(p = 0.18) 18.69(p = 0.096)
-High intensity No. of trials 5 18
Odds ratio 1.99 1.73
95% CI 1.49–2.64 1.51–1.99
Χ2 & p for heterogeneity 2.55 (p = 0.64) 23.06 (p = 0.15)
c) Length of follow-up subgroups: No. of trials 3 11
-6 months Odds ratio 1.96 1.96
95% CI 1.44–2.66 1.65–2.34
Χ2 & p for heterogeneity 1.74(p = 0.72) 8.06 (p = 0.62)
-12 months No. of trials 6 19
Odds ratio 2.09 1.62
95% CI 1.39–3.12 1.42–1.84
Χ2 & p for heterogeneity 2.38 (p = 0.67) 30.67 (p = 0.044)
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and the estimate for the trials included subsequently (OR
1.65, 95% CI 1.47–1.85, X2 = 7.08, p = 0.095) was not
statistically significant (test for interaction, P = 0.14).
We considered characteristics of the trials that might ex-
plain some of the change in the overall estimate.
Amongst the explanations we considered a priori were
that relative efficacy might differ by setting of care (and
hence case mix) and level of support [7], or according to
length of follow-up. Of the studies available in 1994, all
but three recruited community volunteers. Two were in
primary care, and one was in hospital patients. Since
then, large studies have been done in primary care [8,9]
and in a Veterans Administration Medical Centre [10]. In
2000 the estimated effect size for primary care trials
alone was 1.47 (95% CI 1.18 – 1.83), which was lower
than that in community volunteers (1.86, 95% CI 1.62 –
2.14). This difference is not statistically significant (P =
0.075). There is evidence from control quit rates that the
level of motivation to quit was lower in primary care set-
tings, but there is little evidence that the characteristics
of the participants has changed. Most trials recruit heav-
ier smokers irrespective of setting.
In 1994 the sub group analysis distinguishing trials with
high and low intensity support showed a non-significant
trend towards the patch having a larger relative benefit
when used in conjunction with low intensity support.
There were four trials in the low intensity support sub
group and five in the high intensity group. The 2000 re-
view, with 12 low intensity and 18 high intensity trials
shows no evidence for such a difference. (Table 2b)
Length of follow-up
In the 1994 meta-analysis, three nicotine patch trials,
containing over 50% of the total participants, reported
cessation rates at 6 months, and six trials reported 12
month follow-up data. The odds ratios for each subgroup
were similar, and overall heterogeneity was low, so all
were pooled. To investigate whether this was still appro-
priate we compared subgroups by length of follow-up.
For the 19 trials that now report 12 month outcomes
(66% of the total) the pooled estimate was lower (OR
1.62, 95% CI 1.42 – 1.84) than for the 11 with 6 month
outcomes (OR 1.96, 95% CI 1.65–2.34). However, the
difference between these odds ratios was not statistically
significant (p = 0.085). Heterogeneity was low amongst
the 6 month trials, but was statistically significant in the
12 month trial subgroup (p = 0.044). (Table 2c)
Qualitative changes in the systematic review
In 1994 the meta-analysis addressed two central ques-
tions: 1. The effectiveness of any type of nicotine replace-
ment therapy compared to placebo 2. The effect of
different doses estimated by indirect comparison. In
2000, the meta-analysis examined, in addition, the effect
of new forms of NRT (nasal spray, inhalator, tablet), the
effect of combinations of NRT (for example, patch plus
inhaler versus patch alone), direct comparisons of differ-
ent doses of NRT, and NRT versus non-nicotine pharma-
cotherapies such as the antidepressant, bupropion. Only
one trial has so far addressed this question. [11]
Discussion
Since 1994, a large number of trials of NRT have been re-
ported. Meta-analytic estimates of the effects of the nic-
otine patch were lower in 2000 than in 1994, but there
was no difference in statistical significance. The clinical
message, that NRT can help dependent smokers to quit,
is unchanged. Sub-group analyses, even when pre-speci-
fied, can lead to over-interpretation of findings of bor-
derline significance. The updated meta-analysis shows
that this was the explanation for possible differences in
relative effect by level of behavioural support for gum
and patch suggested by sub-group analysis in 1994. Ab-
solute quit rates differ substantially according to such
factors as baseline motivation of the population studied
and the intensity of adjunctive behavioural support of-
fered. The updated review provides further evidence that
the relative effectiveness of treatment does not vary sig-
nificantly among these sub-groups. Our other explorato-
ry analyses similarly failed to detect a significant
difference in relative effects due to changing case mix or
length of follow-up. This is in keeping with evidence
from other conditions that relative effects are often con-
stant across different levels of baseline risk [12].
One reason for lower estimates of effectiveness over time
may be a form of publication bias in which trials with
negative, or less encouraging results, take longer to reach
publication. [13] We were unable to explore this because
few trials specified the date when they started recruit-
ment. However, chance provides an adequate explana-
tion for the lower estimates of the effectiveness of NRT in
2000, without the need to invoke systematic bias.
The content of the review has changed significantly, now
including data on issues that were not included in the
1994 review, and in some cases, not flagged by the review
as areas to be addressed in the future. This presents a di-
lemma for research synthesis. One principle of the sys-
tematic review is that it should work to a protocol,
recognising the possibility of bias if the review takes its
structure from the available evidence rather than vice
versa. On the other hand, clinical practice and research
move on, sometimes in unanticipated ways. Updated re-
views that ignore new questions and data risk being per-
ceived as irrelevant and out of touch. Our compromise
solution has been to review the protocol annually prior to
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to be particularly cautious in drawing conclusions about
new questions based on emerging and incomplete pri-
mary evidence.
Conclusions
What did updating achieve in this example? The main ef-
fect of accumulating further evidence from placebo-con-
trolled trials of nicotine replacement was to reduce the
risk of drawing spurious conclusions from sub-group
analyses. Overall estimates of the effect of nicotine re-
placement in helping people to give up smoking have not
changed significantly. The huge investment in placebo-
controlled trials in the 1990's therefore added little to
overall knowledge. This raises two separate issues. First,
further placebo-controlled trials should not be funded.
The relative effects of NRT differ little by patient charac-
teristics, and the need to demonstrate efficacy in partic-
ular subgroups (for example, in patients with chronic
disease) should be challenged. The second, and more dif-
ficult issue, is whether systematic reviews should contin-
ue to be updated with studies that will not change the
cumulative conclusions. There are examples, of appar-
ently robust pooled estimates that have been challenged
by results from very large randomised trials. [14] A policy
of not updating reviews would violate the principle that
systematic reviews should consider all the available evi-
dence, and would be a form of bias by date of publication.
On the other hand, updating consumes resources, which
are wasted if the conclusions do not change. Either way,
greater attention to cumulative knowledge in determin-
ing the questions to be addressed in primary research is
important to ensure that neither primary nor secondary
research wastes resources on questions that have been
adequately answered.
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